Inflammation News and Research

RSS

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.

26 Dec 2011

Cleveland Clinic scientists named AAAS Fellows

Cleveland Clinic researchers Bruce Lamb, Ph.D., and Xiaoxia Li, Ph.D., were recently named Fellows of the American Association for the Advancement of Science.

26 Dec 2011

Researchers evaluate role of Mediterranean diet ingredients in prevention of cell damage

The researchers evaluated the role of Mediterranean diet ingredients in the prevention and mitigation of cell damage.

23 Dec 2011

Faulty lipid metabolism may cause MS, says forensic anthropologist

An article to be published in the December 2011 issue of The Quarterly Review of Biology argues that multiple sclerosis, long viewed as primarily an autoimmune disease, is not actually a disease of the immune system.

23 Dec 2011

Scientists discover mechanism by which TNFα stimulates tumor formation

An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

23 Dec 2011

ViroPharma to acquire Meritage

ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.

23 Dec 2011

Inhibition of necroptosis protects mice from lethal SIRS

Sepsis, a form of systemic inflammation, is the leading cause of death in critically ill patients. Sepsis is linked with massive cell death; however, the specific mechanisms involved in the lethality of sepsis are unclear. Now, a new study published by Cell Press in the December 23rd issue of the journal Immunity finds that inhibition of a specific cell death pathway called "necroptosis" protected mice from lethal inflammation.

23 Dec 2011

FDA, other organizations unveil program to monitor cataract surgery devices

The U.S. Food and Drug Administration and other government and professional organizations today unveiled a program to monitor medical devices used in cataract surgery in an effort to stem outbreaks of a rare, inflammatory condition associated with the procedure.

21 Dec 2011

Scientists identify why African naked mole-rat feels no pain when exposed to acid

British researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have found out why the African naked mole-rat (Heterocephalus glaber), one of the world's most unusual mammals, feels no pain when exposed to acid.

21 Dec 2011

Study assesses evidence of immunosuppression in sepsis

An analysis of lung and spleen tissue from patients who died of sepsis revealed certain biochemical, cellular and histological findings that were consistent with immunosuppression, according to a study in the December 21 issue of JAMA.

21 Dec 2011

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

Immunosuppressant combination improves survival of human spinal stem cells in ALS rat model

A team of researchers grafting human spinal stem cells into rats modeled with amyotrophic lateral sclerosis (ALS), also known as "Lou Gehrig's Disease," a degenerative, lethal, neuromuscular disease, have tested four different immunosuppressive protocols aimed at determining which regimen improved long-term therapeutic effects.

20 Dec 2011

EETs may also drive growth and spread of cancer

A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.

20 Dec 2011

Scientists discover missing link between body's biological clock and sugar metabolism system

Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.

20 Dec 2011

Children with SDB may have better QOL after adenotonsillectomy

Children may have a better quality of life (QOL) and diminished cardiovascular disease risk from the decreased endothelin 1 (ET-1) levels after adenotonsillectomy, according to new research published in the December 2011 issue of Otolaryngology - Head and Neck Surgery.

20 Dec 2011

Blocking EETs may represent novel strategy for cancer therapy

Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.

20 Dec 2011

Second-hand smoke exposure during childhood associated with aspirin-exacerbated respiratory disease

Need another reason to keep your New Year's resolution to stop smoking? A first-of-its-kind study found adults with aspirin-exacerbated respiratory disease were more than three times as likely to have been exposed to second-hand smoke during childhood as those without the condition.

19 Dec 2011

arGEN-X to advance SIMPLE Antibody platform for treatment of autoimmune disorders

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today it has received a grant of €1.3 million to further advance its powerful discovery platform for addressing challenging disease targets.

19 Dec 2011

Increased Sirt1 expression protects against neurodegeneration in HD mouse model

Treatment that increases brain levels of an important regulatory enzyme may slow the loss of brain cells that characterizes Huntington's disease (HD) and other neurodegenerative disorders.

19 Dec 2011

Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma

The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.

17 Dec 2011